INVESTMENTS THAT MATTER

Agent Capital is a healthcare venture capital firm focused on investing in novel, differentiated therapeutics and treatments that address unmet patient needs.

Across all stages of development, we align ourselves with scientists, entrepreneurs and other investors to develop the next generation of healthcare innovations that will have a positive impact on patients’ lives.

OUR PROVEN STRATEGY

At Agent Capital, we proactively guide biotech companies to milestones and exits.

With a balanced investment approach and a deep understanding of biopharma’s pipeline pressures, we are committed to making investments that move healthcare forward – no matter the stage or investment type.

TYPICALLY, OUR KEY INVESTMENT AREAS OF FOCUS INCLUDE:

Rare Diseases
Oncology
Neurology
Immunology
Learn More

Featured Portfolio Company

Dice Therapeutics

Freenome

Metagenomi

Pliant Therapeutics

ViTToria Biotherapeutics

Dragonfly Therapeutics

Carisma Therapeutics

Skyhawk Therapeutics

Flare Therapeutics

ImCheck Therapeutics

Orchard Therapeutics

Entrada Therapeutics

Zenas Biopharma

Star Therapeutics

Pyxis Oncology

Precision Biosciences

Palvella Therapeutics

View Full Portfolio

Featured News

News | October 14, 2024

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

Read More

News | October 10, 2024

Cyrus Biotechnology Congratulates David Baker, 2024 Nobel Laureate in Chemistry and Cyrus Co-Founder

Read More

Press Release | September 17, 2024

āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors

Read More

View All